Background: Spain needs to increase the number of new known cases in order to
INTRODUCTION
According to the latest official data published by the Spanish Ministry of Health (6) , the preliminary data from the last national seroprevalence study in the general population is 0.80%. Several other HCV seroprevalence surveys at the regional level provide similar data: Navarra 0.83% (95% CI: 0.64-1.05%) (7), Basque Country 0.7% (95% CI: 0.3-1.2%) (8) , Valencia 1.14% (95% CI: 0.73-1.55%) (9), Ethon-cohort (Valencia, Cantabria and Madrid) 1.23% (10) and Catalonia 1.1% (11). According to data published by the Spanish Government (6), more than 117,000 people with HCV have been treated with the new direct acting antiviral (DAA) drugs in Spain as of the end of 2018. Even after this notable achievement by the Spanish National Health System, there are further challenges for the design of targeted and efficient secondary prevention programs that are capable of diagnosing undetected cases. Furthermore, new studies highlight the risk of "diagnostic burn-out" and there is a need to change the current screening strategies in order to reach more people and the goal of hepatitis C elimination in Spain (12) .
In Spain, the screening recommendations for HCV are laid out in the "Strategic Plan for Tackling Hepatitis C in the Spanish National Health System" (13) . The different risk groups are defined as people who inject drugs (PWID), people living with HIV (PLWH), men who have sex with men (MSM) and people with tattoos or piercings, among others. Nevertheless, migrants from countries with a moderate or high prevalence of HCV are not included in these screening recommendations.
The strategy of the WHO is to eliminate this disease and promote the screening for HCV in at risk groups, such as immigrants from countries with an endemicity of 2-5% or higher (2,14). In addition, other countries such as the United Kingdom, Ireland and Canada offer opportunistic screening programs and/or campaigns to detect new cases among the immigrant populations arriving from endemic countries (15-17).
In Spain, there are more than six million immigrants from more than 100 countries (18) . The European Centre for Disease Prevention and Control (ECDC) made a first approach with demographic data from 2013. This study estimated that there were more than 50,000 chronic cases among immigrants in Spain, when considering only the top 10 countries that contributed to the greatest number of cases. However, there are no data for the estimated case distribution among the 17 autonomous communities (AC) and 50 Spanish provinces.
Due to the lack of data and comprehensive epidemiological studies in Spain, and based on the ECDC's study approach, this study aimed to report an estimated figure of migrants with anti-HCV+ and viremic HCV in Spain. Furthermore, four different screening strategy scenarios were proposed according to the threshold of prevalence being considered.
METHODS
This is a descriptive cross-sectional study that used demographic data of the foreignborn population stratified by country of birth for each of the 50 Spanish provinces and two autonomous cities (Ceuta and Melilla). These were obtained from the National Statistics Institute (INE) on the 1 st of January of 2016 (18) . The study population included the adolescent/adult migrant population defined as those ≥ 15 years/old who were born in countries other than Spain (including both foreign and nationalized Spanish citizens). The limit of ≥ 15 years old was established based on a meta-analysis and also on the ECDC's report, which calculated and established the country anti-HCV+ prevalence for a population ≥ 15 years-old (19, 20) . The prevalence of anti-HCV+ for every country was obtained from the ECDC technical report, which assesses the epidemiological data of hepatitis in immigrants in the European Union (EU) (19) . The number of infected or anti-HCV+ cases among immigrants in every province was estimated from both sources with the assumption that the HCV prevalence in each country of birth is the probability of being infected within each group of migrants. (Table 1) .
Analysis by different screening scenarios at a national level
The hypothetical scenario of the HCV screening program for migrants has a ≥ 2% Countries such as Albania, Gambia, Israel, Latvia or Thailand would be included in a screening program under scenario A (prevalence ≥ 2%). However, they would be excluded in other scenarios.
Analysis by different screening scenarios and autonomous community (AC)
Only the results for scenarios A, C and D are shown due to the fact that the difference between scenario A and B is only 950 cases (0.94%). The number of adult migrant population included in scenario A (from countries with an anti-HCV+ prevalence ≥ 2%)
for every AC and the number of estimated anti-HCV+ cases (and its lower and upper limit) is shown in table 1. Data for every AC for migrants from countries with an HCV prevalence ≥ 4% and ≥ 5% (scenario C and D, respectively) are also shown in table 1. 
Spatial analysis by screening scenarios and provinces

Analysis by country of origin and province
The results of the number of estimated anti-HCV+ cases by country of origin and province are shown in table 3.
DISCUSSION
Our study estimates that approximately 100,000 immigrants are anti-HCV+ in Spain, 70,000 estimated viremic cases with an average anti-HCV+ prevalence of 1.7%.
However, the number of people treated and with a potentially eliminated infection should also be considered. According to a prevalence study conducted in the Navarre population, 7% of all anti-HCV+ cases are migrants (7) . Considering that all migrants would have equally accessed treatment in Spain, we estimate that 8,222 migrants have been treated for HCV (7% of 117,452 treated people in Spain) and therefore have been cured. Thus, a total of 61,778 migrants would potentially benefit from a screening program.
We could consider different threshold cut-offs for establishing high HCV endemicity, New screening targets and different strategies to increase the number of unknown anti-HCV+ are needed (22) . Researchers warn that Spain and other countries, although they effectively diagnose and treat HCV, may have problems eliminating the epidemics due to "diagnostic burnout". This is the stage where no more newly diagnosed people are available for treatment (12) .
Migrants have been identified as important sub-groups that should be specifically addressed as part of the hepatitis C efforts and micro-elimination activities (23) . To address HCV among migrants in Spain, the following three micro-elimination strategies are proposed.
Micro-elimination tailored strategy based on country of birth
The high-risk migrant groups living in Spain were identified based on the HCV prevalence of the country of origin among the immigrant population who lived in Spain. Considering the country of origin of these high-risk groups, some of the endemic countries with the highest number of estimated cases in Spain are Romania, Italy, Pakistan, Ukraine and Senegal. The countries with a higher prevalence and therefore a higher probability of being infected with HCV in Spain are Egypt (anti-HCV+ prevalence: 15%) and Cameroon (11%). However, these two countries contribute very little to the total estimated cases in Spain due to a low number of people from these countries living in Spain.
The high contribution of Italians to the burden of HCV cases in migrants is due to the high number of Italian people living in Spain and also due to the traditionally high HCV prevalence in this country. This may be related to previous intravenous drug and nosocomial transmission, among others. Migration movements may have also been partially responsible for the high prevalence, particularly in the last two decades where the incidence in autochthonous population has decreased. Active surveillance is needed to better understand if the incoming migrants could modify the current epidemiological trends in the host population in Italy (24) .
Micro-elimination strategy based on geographically defined areas
In our study, the distribution of estimated cases among different regions was assessed, 
Strategies with a province, autonomic or State administrative level
The geographical distribution of positive cases also depends on the country of origin.
Accordingly, the number of anti-HCV+ estimated cases from Romania is homogeneously distributed across all provinces in Spain, while cases in the Pakistani population are mainly found in the eastern Spanish provinces. It is remarkable that the province of Barcelona alone has 50% of the total estimated anti-HCV+ cases of people from Pakistan.
As every AC in Spain has its own Autonomous Health System and some AC are more affected than others, we recommend establishing prevention and control policies for hepatitis C that are targeted towards sub-populations that require more attention, after studying and understanding the immigrant context in every province.
However, a national or state screening program should also be proposed for migrants from a particular origin that are more homogeneously distributed across Spain, for example Romania. It should be highlighted that if such a measure was implemented that only targeted the Romanian immigrant population (with a prevalence of 3.2% in the country of origin), 19,200 estimated anti-HCV+ cases (13,400 viremic cases) could benefit from this screening. This would result in 40% of the total estimated cases among immigrants from endemic countries (≥ 2%). These data are comparable to the estimations of the ECDC of approximately 14,800 viremic cases amongst Romanians in Spain (19) .
However, a possible limitation in our study, which seems to be a controversial issue, is the percentage of viral clearance in relation to anti-HCV+. Although many studies have established that around 70% are viremic cases (19, 20) , recent preliminary data (from the national seroprevalence survey, performed at primary health centers [6] ) report a marked reduction in this percentage. Nevertheless, these low figures should be studied and updated, detailing when they are available (6).
The ECDC recognized in its report (2016) that the use of HCV prevalence in the country of origin is a limitation for the calculation of estimated cases (19) . Likewise, this assumption is also considered as the main limitation of our study. Although it could be justified by the lack of any other epidemiologic study at the national level that provides prevalence data by country of origin. In fact, only a few studies exist in Spain that consist of small cohorts followed by Tropical Diseases Hospital Units, which could overestimate the prevalence in these groups (25) (26) (27) . On the other hand, seroprevalence surveys that target the Spanish general population are not usually representative of the immigrant groups and/or the results by country are not often available (7, 8, 28) . Moreover, our data can benefit from the design of new studies that sample immigrates in Spain to confirm that the country HCV prevalence is similar to The Spanish National Strategy of hepatitis C calls every AC to action to take measures on the Hepatitis C Prevention and Control programs. Furthermore, the immigrant population from endemic countries are not explicitly mentioned in the HCV screening national protocol (13) . This could offer a great opportunity to add this target population in order to reach the goal of hepatitis C elimination in Spain. Viral hepatitis cannot be eliminated without reaching this population.
The data from our study may help to identify which groups of immigrants could benefit greatly from local screening programs since it reports data of the distribution of HCV cases among immigrants by region and province. Thus, providing useful information for each AC surveillance health system in order to facilitate the design of tailored HCV programs. Further studies that assess the HCV prevalence in migrants living in the different Spanish areas, the acceptability of HCV screening programs among migrants, or a cost-effectiveness analysis of these strategies in the context of each Autonomous Health System are necessary before implementing a screening program in migrant populations from high-endemic countries.
CONCLUSIONS
This study determined HCV estimated cases among migrants, demonstrating that they are an important group in order to address the elimination efforts. Targeted screening efforts, which are based on subgroups according to the country of origin and the place of residence are needed to engage this population in prevention, treatment and care within Spain.
Note to the editor: analysis by Autonomous Community and countries with anti-HCV+ prevalence ≥ 2% can be consulted on-line in an extra-supplement (17 extra tables). 
